$5.93
0.00% yesterday
Nasdaq, Dec 24, 10:27 pm CET
ISIN
US56400P7069
Symbol
MNKD

MannKind Corporation Stock price

$5.93
+0.80 15.59% 1M
+1.94 48.62% 6M
-0.50 7.78% YTD
-0.81 12.02% 1Y
+0.84 16.50% 3Y
+2.51 73.39% 5Y
-1.72 22.48% 10Y
-53.37 90.00% 20Y
Nasdaq, Closing price Wed, Dec 24 2025
+0.00 0.00%
ISIN
US56400P7069
Symbol
MNKD
Industry

Key metrics

Basic
Market capitalization
$1.8b
Enterprise Value
$1.9b
Net debt
$103.9m
Cash
$260.0m
Shares outstanding
307.0m
Valuation (TTM | estimate)
P/E
65.9 | 74.5
P/S
5.8 | 5.2
EV/Sales
6.1 | 5.5
EV/FCF
44.4
P/B
negative
Financial Health
Equity Ratio
-20.0%
Return on Equity
-35.0%
ROCE
22.4%
ROIC
39.9%
Debt/Equity
-8.2
Financials (TTM | estimate)
Revenue
$313.8m | $347.0m
EBITDA
$94.6m | -
EBIT
$86.2m | $78.3m
Net Income
$28.8m | $24.4m
Free Cash Flow
$43.4m
Growth (TTM | estimate)
Revenue
17.4% | 21.5%
EBITDA
46.5% | -
EBIT
48.3% | 7.9%
Net Income
33.3% | -11.5%
Free Cash Flow
50.3%
Margin (TTM | estimate)
Gross
78.5%
EBITDA
30.2% | -
EBIT
27.5%
Net
9.2% | 7.0%
Free Cash Flow
13.8%
More
EPS
$0.1
FCF per Share
$0.1
Short interest
7.6%
Employees
405
Rev per Employee
$700.0k
Show more

Is MannKind Corporation a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,079 stocks worldwide.

MannKind Corporation Stock Analysis

Unlock Scores for Free

Analyst Opinions

15 Analysts have issued a MannKind Corporation forecast:

14x Buy
93%
1x Hold
7%

Analyst Opinions

15 Analysts have issued a MannKind Corporation forecast:

Buy
93%
Hold
7%

Financial data from MannKind Corporation

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
314 314
17% 17%
100%
- Direct Costs 67 67
9% 9%
22%
246 246
28% 28%
78%
- Selling and Administrative Expenses 110 110
21% 21%
35%
- Research and Development Expense 50 50
13% 13%
16%
95 95
47% 47%
30%
- Depreciation and Amortization 8.41 8.41
31% 31%
3%
EBIT (Operating Income) EBIT 86 86
48% 48%
27%
Net Profit 29 29
33% 33%
9%

In millions USD.

Don't miss a Thing! We will send you all news about MannKind Corporation directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

MannKind Corporation Stock News

Neutral
The Motley Fool
about 20 hours ago
On Dec. 17, 2025, Michael Castagna, Chief Executive Officer of MannKind Corporation (MNKD +0.00%), executed an exercise and immediate sale of 65,804 common shares for a transaction value of approximately $395,482, according to the SEC Form 4 filing.
Neutral
GlobeNewsWire
2 days ago
FDA approves FUROSCIX ® for use in pediatric patients weighing 43kg or above USPTO issues five patents for FUROSCIX ReadyFlow ™ Autoinjector WESTLAKE VILLAGE, Calif. and BURLINGTON, Mass.
Positive
Seeking Alpha
22 days ago
MannKind Corporation delivered strong Q3 '25 results, beating EPS and revenue estimates, and shares have responded positively. The FDA accepted the supplemental New Drug Application for the FUROSCIX ReadyFlow Autoinjector, offering rapid furosemide delivery for CHF and CKD patients. I see a substantial TAM, estimating 670,000 to 1.34 million potential U.S. heart failure patients for ReadyFlow, ...
More MannKind Corporation News

Company Profile

MannKind Corp. is a biopharmaceutical company. It focuses on the discovery, development and, commercialization of therapeutic products for diseases, such as diabetes and cancer. The company was founded by Alfred E. Mann on February 14, 1991 and is headquartered in Westlake Village, CA.

Head office United States
CEO Michael Castagna
Employees 405
Founded 1991
Website mannkindcorp.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today